Evidence map›Paper›PMID 36287976›Full record

ArticleToxins2022

Botulinum Neurotoxin Type A Directly Affects Sebocytes and Modulates Oleic Acid-Induced Lipogenesis.

Karen Brami-Cherrier, Alex Chernavsky, Hui You, Sergei A Grando, Amy Brideau-Andersen, Birgitte Sondergaard

Open access · goldAbstract read
In one paragraph

Article in Toxins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Karen Brami-CherrierNeurotoxin Research Program, Department of Biological Sciences, Allergan Aesthetics, an AbbVie Company, Irvine, CA 92612, USA.
Alex ChernavskyDepartment of Dermatology, University of California Irvine, Irvine, CA 92617, USA.
Hui YouNeurotoxin Research Program, Department of Biological Sciences, Allergan Aesthetics, an AbbVie Company, Irvine, CA 92612, USA.
Sergei A GrandoDepartment of Dermatology, University of California Irvine, Irvine, CA 92617, USA.
Amy Brideau-AndersenNeurotoxin Research Program, Department of Biological Sciences, Allergan Aesthetics, an AbbVie Company, Irvine, CA 92612, USA.
Birgitte SondergaardNeurotoxin Research Program, Department of Biological Sciences, Allergan Aesthetics, an AbbVie Company, Irvine, CA 92612, USA.
AbbVie (United States) · USAllergan (United States) · USUniversity of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Excess sebum (seborrhea) results in oily skin and is associated with large pore size and acne. Studies in healthy, seborrheic volunteers have reported that intradermal injection of commercial preparations of botulinum neurotoxin type A (BoNT/A) (onabotulinumtoxinA, abobotulinumtoxinA, and incobotulinumtoxinA) reduced sebum production, and thus, skin oiliness and pore size. The mechanism for these effects has not been fully elucidated; however, several theories involving direct or indirect effects of BoNT/A on neuronal and/or dermal cells (e.g., sebocytes) have been proposed. In the present study, we evaluated the direct effect of native research grade BoNT/A complex, a commercial preparation of BoNT/A (onabotA), and BoNT/A variants on sebocyte lipogenesis using an in vitro sebocyte cell model. We show that picomolar concentrations of BoNT/A (BoNT/A complex: half maximal effective concentration [EC

Indexed as

Botulinum Toxins, Type AHumansLipogenesisOleic AcidReceptors, Cell SurfaceReceptors, Fibroblast Growth FactorBotulinum Toxins, Type AOleic AcidReceptors, Cell SurfaceReceptors, Fibroblast Growth Factor5α-dihydrotestosteroneacnebinding domainBOTOX®fibroblast growth factoroilinessonabotulinumtoxinAseborrheasebumskin

Identifiers

PMID36287976
PMCPMC9609209
OpenAlexW4306404423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.